Radiolabelled peptides for tumour therapy: current status and future directions
- 5 February 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (3), 463-469
- https://doi.org/10.1007/s00259-002-1107-8
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology groupSeminars in Nuclear Medicine, 2002
- DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapyJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- Receptor-mediated radiotherapy with 90Y-DOTATOC: Towards the right doseNuclear Medicine Communications, 2000
- Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human BreastThe American Journal of Pathology, 1999
- Visualization of the thymus by substance P receptor scintigraphy in manEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractNuclear Medicine and Biology, 1996
- Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Somatostatin receptors in malignant tissuesThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989